This site is intended for UK-registered healthcare professionals only
Media partners:
Prescribing Information and adverse events reporting information can be found at the bottom of this page.
This website has been developed and funded by A. Menarini Farmaceutica Internazionale SRL. The Improving Diabetes Steering Committee is supported by an educational grant from A. Menarini Farmaceutica Internazionale SRL. The SGLT2 Inhibitor Prescribing Decision Tool has been independently prepared by the IDSC. The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.
The Improving Diabetes Steering Committee (IDSC) – a multidisciplinary group of experts across primary and secondary care – aims to support healthcare professionals by producing materials that provide balanced reviews of the evidence and guidelines relating to use of SGLT2 inhibitors in the management of type 2 diabetes, including their risk/benefit profile in reducing the risk of cardiovascular, renal and metabolic (CVRM) complications.
The tools and resources developed by the IDSC and collated in this hub aim to build greater confidence regarding the use of SGLT2 inhibitors in type 2 diabetes management, helping to bridge the gap between current guidelines and prescribing practices.
Use our evidence-led, interactive SGLT2 Inhibitor Prescribing Decision Tool for a quick reference guide that supports you in making appropriate prescribing decisions in clinical practice.
The handy traffic light system provides clarity regarding common areas of confusion, including the early and late use of SGLT2 inhibitors and complication risk.
The SGLT2 Inhibitor Prescribing Decision Tool has been independently prepared by the IDSC. A. Menarini Farmaceutica Internazionale SRL has fully funded the development of the SGLT2 Inhibitor Prescribing Decision Tool wallchart.
Watch Professor David Wheeler and Jane Diggle walk through the practicalities of the SGLT2 Inhibitor Prescribing Decision Tool for type 2 diabetes management and how you can access the IDSC resources.
Join Lisa Kelly as she interviews Professor John Wilding on his role in the IDSC, their previous and most recent outputs, and how the materials they produce aim to benefit both healthcare professionals and people living with type 2 diabetes.
Watch Lisa Kelly and Phillip Newland-Jones discuss the importance of concomitant treatment in diabetes and other cardiorenal metabolic diseases, and how the tools developed by the IDSC can help both healthcare professionals and patients with type 2 diabetes.
Hear Lisa Kelly and Professor David Wheeler discuss the latest guideline-based narrative review by the IDSC, and the link between diabetes and kidney disease.
Watch Dr Kevin Fernando talk about the impact the IDSC has had over the past six years – from five narrative reviews to evidence- and guideline-based prescribing decision tools.
Jane Diggle discusses her involvement with the IDSC, and the outputs and impact this interdisciplinary expert group has had in the diabetes landscape.
The IDSC has published five narrative reviews1–5 that reflect the growing evidence surrounding SGLT2 inhibitors in type 2 diabetes and aim to translate these evidence into clinical practice.
The most recent narrative review5 summarises the value of SGLT2 inhibitors in treating cardiovascular, renal and metabolic diseases, and places the relative risks into context.
The IDSC has published five narrative reviews1–5 that reflect the growing evidence surrounding SGLT2 inhibitors in type 2 diabetes and aim to translate this evidence into clinical practice.
The most recent narrative review5 summarises the value of SGLT2 inhibitors in treating CVRM diseases, and places the relative risks into context.
The above link will direct you to a third-party website. A. Menarini Farmaceutica Internazionale SRL and the media partners have had no input into the content of this website.
CVRM: cardiovascular, renal and metabolic; IDSC: Improving Diabetes Steering Committee; SGLT2: sodium-glucose co-transporter-2
CVRM: cardiovascular, renal and metabolic; IDSC: Improving Diabetes Steering Committee; SGLT2: sodium-glucose co-transporter-2
References
Invokana® (canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
Refer to SmPC for full indications.
Click here for Invokana® (canagliflozin) Great Britain Prescribing Information. Click here for Invokana® (canagliflozin) Northern Ireland Prescribing Information.
This website has been developed and funded by A. Menarini Farmaceutica Internazionale SRL. The Improving Diabetes Steering Committee is supported by an educational grant from A. Menarini Farmaceutica Internazionale SRL. The SGLT2 Inhibitor Prescribing Decision Tool has been independently prepared by the IDSC. The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL on 0800 085 8678 or by e-mail: [email protected]
PP-IN-UK-1449 | June 2024
A. Menarini Farmaceutica Internazionale SRL have had no input into the contents of the footer and are not affiliated with the links. GPnotebook is responsible for the contents of the footer.
The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2024 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.
To continue, please confirm that you are a UK-registered healthcare professional by clicking one of the buttons below
Tirzepatide is recommended for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if:
Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.
Reference: 10. © NICE 2023 Tirzepatide for treating type 2 diabetes. Available from https://www.nice.org.uk/
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
for treating type 2 diabetes10